BIOXYTRAN, INC
For the period ended Jun 30, 2025. Filed Aug 11, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 11, 2025
BIXTStored price and day change unavailable
What changed in Management’s Discussion and Analysis?
Read the current filingPrevious report: 10-Q
Period ended 2025-03-31; filed 2025-05-15.
0001641172-25-010822
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of OperationsCurrent report: 10-Q
Period ended 2025-06-30; filed 2025-08-11.
0001493152-25-011797
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of OperationsThe baseline is this issuer’s latest earlier reporting period of the same form that was filed before the current report. A previous 10-Q is a different quarter, not a year-over-year comparison. Amendments are excluded.
Compared 60 previous paragraphs and 32 current paragraphs.
28 unchanged; 2 reworded; 2 added; 30 removed; 0 previous and 0 current paragraphs rearranged.
Tables are not compared: 13 previous and 24 current tables excluded. Dates, whitespace, punctuation and numbering changes are ignored; changes to financial figures remain significant.
A changed paragraph is not evidence that risk increased or decreased. An unchanged paragraph does not establish that risk stayed the same.
Added paragraphs (2)
Current report
RESULTS OF OPERATIONS FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2025, AND 2024
Current report
Upcoming Financing Activities
Removed paragraphs (30)
Previous report
RESULTS OF OPERATIONS
Previous report
Research and Development
Previous report
During the three months ended March 31, 2025, the Company recorded $349,500 in R&D expenses. During the three months ended March 31, 2024, the Company recorded $27,000.
Previous report
General and Administrative
Previous report
The significant decrease in Payroll and related expenses for the three months ended March 31, 2025, were due to the Company’s Officers forfeiting $578,959 in accrued payroll.
Previous report
The Costs for legal, accounting and other professional services ended up at $59,670 (whereof $5,000 was affiliate related) for the three months ended March 31, 2025, and $2,114 for the three months ended March 31, 2024.
Previous report
Sales and marketing expense for the three months ended March 31, 2025, were $15,000, as compared to $22,000 for the three months ended March 31, 2024. The decrease costs are due to reduced stock promotional activities in 2025.
Previous report
Miscellaneous G&A expenses during the three months ended March 31, 2025, and 2024, was $62,689 and $50,748, respectively.
Previous report
Stock-based compensation mounted to $26,998 for the three months ended March 31, 2025, (whereof $16,251 to affiliates). The stock-based compensation for the three months ended March 31, 2024, was $300,245, (whereof $131,835 for affiliates).
Previous report
Other (income) expenses
Previous report
During the three months ended March 31, 2025, the Company recorded an $804,752 change in derivative fair value due to an increased market price of the Company’s Common shares, while theinterest expensewas $31,890 (whereof $733 to affiliates), $1,851 was amortized from the Company’s IP. During the three months ended March 31, 2024, the Company recorded aninterest expense of $27,831 (whereof $1,457 to affiliates), $2,031 was amortized from the Company’s IP and a gain on issuance of $235,245 was accounted for due to incorrect valuation of issued shares.
Previous report
For the three months ended March 31, 2024, there was a non-controlling interest attribution of $13,324, 100% of the subsidiaries shares were acquired in 2024, why the attribution of $13,324 is for the period prior to the acquisition.
Previous report
Net Loss
Previous report
The Company generated a net loss for the three months ended March 31, 2025, of $1,353,635. In comparison, for the three months ended March 31, 2024, the Company generated a net loss of $560,522. The significant difference is due to the Company’s valuation of it’s derivative debt.
Previous report
CASH-FLOWS
Previous report
Net cash used in operating activities was $(167,323) and $(109,567) for the three months ended March 31, 2025, and 2024, respectively.
Previous report
Net cash used in investing activities: In the three months ended March 31, 2025, the Company is in the process of filing a patent, and $15 was spent in legal fees. In the three months ended March 31, 2024, the amount was $5,995.
Previous report
Cash flows from financing activities were $166,532 and $99,500 for the three months ended March 31, 2025, and 2024, respectively.
Previous report
Theavailable cash was $4,348 and $10,024 in the end of the three months ended March 31, 2025, and 2024, respectively.
Previous report
LIQUIDITY AND CAPITAL RESOURCES
Previous report
Current Assets
Previous report
As of March 31, 2025, our current assets consisted of $4,348 in cash. At December 31, 2024 we had $5,154 in cash.
Previous report
Current Liabilities
Previous report
At March 31, 2025, we had total liabilities of $2,844,089, which consisted of $563,475 in accounts payable and accrued expenses (of which $7,683 was payable to related parties), $28,600 in un-issued shares (of which $16,680 was payable to related parties), and $805,000 in one convertible loan coupled with a derivative liability of $991,404 and $407,610 in a loan from affiliates and $48,000 in other short-term loans. At December 31, 2024, we had total liabilities of $1,930,642, which consisted of $425,544 in accounts payable and accrued expenses (of which $147,286 was payable to related parties), $224,368 in un-issued shares (of which $132,639 was payable to related parties), and $805,000 in one convertible loan coupled with a derivative liability of $186,652 and $241,078 in a loan from affiliates and $48,000 in other short-term loans.
Previous report
Net Working Capital and Accumulated Deficit
Previous report
At March 31, 2025, the net working capital was negative $2,839,741 and the accumulated deficit of $20,274,803. Comparatively, on December 31, 2024, we had net working capital of negative $1,925,488 and the accumulated deficit of $18,921,169. We believe that we must raise not less than $3,700,000 to be able to continue our business operations for the next 15 months.
Previous report
Cash Proceeds from Financing Activities
Previous report
During the three months ending March 31, 2025, the Company had not raised any funds, but borrowed $166,532 from its affiliates. During the three months ending March 31, 2024, the Company had raised $61,500 in form of a convertible note and converted $38,000 from accounts payables to short-term debt. The Company is aware that its current cash on hand will not be sufficient to fund its projected operating requirements through the month of June 2025.
Previous report
Planned Financing Activities
Previous report
As at March 31, 2025, our contractual obligations include one convertible note with a principal of $805,000, the accrued interest for these notes mounting to $174,799. As at December 31, 2024, there were four convertible notes with a principal of $805,000, the accrued interest for these notes mounting to $143,642.
Reworded paragraphs (2)
Previous wording
The accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern. The Company has limited resources and operating history. The Company currently has one convertible loan outstanding at a total face value of $805,000, remaining debt mounts to $1,041,601 (whereof $415,293 is owed to affiliates). As shown in the accompanying consolidated financial statements, the Company had an accumulated deficit of $20,274,803 as at March 31, 2025. The accumulated deficit as at December 31, 2024, was $18,921,169.
Current wording
The accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern. The Company has limited resources and operating history. The Company currently has one convertible loan outstanding at a total face value of $805,000 with an accrued interest of $204,911 and a linked derivative debt of $684,002. The remaining debt mounts to $1,066,136 (whereof $502,255 is owed to affiliates with an accrued interest of $22,948). As shown in the accompanying consolidated financial statements, the Company had an accumulated deficit of $20,239,366 as at June 30, 2025. The accumulated deficit as at December 31, 2024, was $18,921,169.
Previous wording
The Company intends to issue a Private Placement Offering under Regulation D in the order of $4 million in the spring of 2025.
Current wording
Despite the ongoing promotional activities, the Company still struggle with a deflated stock price on OTC Markets which makes it very difficult to raise funds without heavily discounting the price and diluting the shareholders. The Company is actively working on finding financing alternatives in order to continue its regulatory approval activities and intends to issue a Private Placement Offering under Regulation D in the order of $2 million in the spring of 2025.